ADCT vs PFE

For growth investors, ADC Therapeutics S.

A. (ADCT) is the stronger pick with 14. 9% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate ADC Therapeutics S. A. (ADCT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -13. 3%, compared to -84. 1% for ADC Therapeutics S. A. (ADCT). Over 10 years, the gap is even starker: PFE returned +29. 6% versus ADCT's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus ADC Therapeutics S. A. 's 1. 89β — meaning ADCT is approximately 247% more volatile than PFE relative to the S&P 500.

By revenue growth (latest reported year), ADC Therapeutics S.

A. (ADCT) is pulling ahead at 14. 9% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: ADC Therapeutics S. A. grew EPS 30. 9% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, PFE leads at -14. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus -175. 3% for ADC Therapeutics S. A. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -133. 2% for ADCT. At the gross margin level — before operating expenses — ADCT leads at 90. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ADCT: 99.

5% to $7. 50.

In this comparison, PFE (6.

5% yield) pays a dividend. ADCT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). ADC Therapeutics S. A. (ADCT) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +29. 6%, ADCT: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADCT is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while ADCT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.